Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design

David R. Coghill (Lead / Corresponding author), Tobias Banaschewski, Michel Lecendreux, Mats Johnson, Alessandro Zuddas, Colleen S. Anderson, Richard Civil, Matthew Dauphin, Nicholas Higgins, Andrew Lyne, Maria Gasior, Liza A. Squires

    Research output: Contribution to journalArticle

    28 Citations (Scopus)
    186 Downloads (Pure)

    Abstract

    In this phase 3 extension study, the long-term maintenance of efficacy of lisdexamfetamine dimesylate (LDX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) was evaluated using a randomized-withdrawal study design.
    Original languageEnglish
    Pages (from-to)647
    Number of pages657
    JournalJournal of the American Academy of Child & Adolescent Psychiatry
    Volume53
    Issue number6
    Early online date3 Mar 2014
    DOIs
    Publication statusPublished - 2014

      Fingerprint

    Cite this

    Coghill, D. R., Banaschewski, T., Lecendreux, M., Johnson, M., Zuddas, A., Anderson, C. S., Civil, R., Dauphin, M., Higgins, N., Lyne, A., Gasior, M., & Squires, L. A. (2014). Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. Journal of the American Academy of Child & Adolescent Psychiatry, 53(6), 647. https://doi.org/10.1016/j.jaac.2014.01.017